Episode: 57 - The Future Of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D. The Chain: Protein Engineering podcast

Artwork

Science Biology Cambridge Healthtech Institute Proteins Protein Engineering Scientists RD In Antibodies Bispecific Antibodies Solid Tumors

Inhoud geleverd door Cambridge Healthtech Institute. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Cambridge Healthtech Institute of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

The Chain: Protein Engineering Podcast « »
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

6M ago 33:06

Delen

MP3•Thuis aflevering

Inhoud geleverd door Cambridge Healthtech Institute. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Cambridge Healthtech Institute of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.

… continue reading

65 afleveringen

#Science #Biology #Cambridge Healthtech Institute #Proteins #Protein Engineering #Scientists #RD In #Antibodies #Bispecific Antibodies #Solid Tumors

Artwork

Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.

The Chain: Protein Engineering Podcast

published 6M ago

Delen

MP3•Thuis aflevering

Inhoud geleverd door Cambridge Healthtech Institute. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Cambridge Healthtech Institute of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.

… continue reading

65 afleveringen

#Science #Biology #Cambridge Healthtech Institute #Proteins #Protein Engineering #Scientists #RD In #Antibodies #Bispecific Antibodies #Solid Tumors

ทุกตอน

×

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

Luister naar 500+ onderwerpen